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In the present study, we investigated whether age and serious comorbid conditions influence treatment decisions, complications and
survival in breast cancer patients. The Eindhoven Cancer Registry records patient, tumour and therapy characteristics of all patients
diagnosed with cancer in the southern part of the Netherlands. Additional information on severity of comorbidity and serious
complications was collected for a random sample of 527 breast cancer patients (aged 40 years and older). More than 70% of the
patients X80 exhibited high severity of comorbidity compared to 6% of those aged 40–49 years. Treatment was not influenced by
severity of comorbidity. Less than 30% of the breast cancer patients had complications after diagnosis. The number of complications
was not related to age or severity of comorbidity. The hazard ratio (HR) of dying for patients with low/moderate severity of
comorbidity was 2.4 for those aged 40–69 years and 1.6 for those aged X70 years, after adjustment for age, nodal status and
treatment. For patients with high severity of comorbidity, the risk of dying was almost three times higher. Older breast cancer patients
with serious comorbidity were not treated differently and did not have more complications compared to those without comorbidity,
but they exhibited a worse prognosis.
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Comorbidity, the coexistence of various chronic illnesses in
addition to the index disease, is an increasing problem in
industrialised countries due to the rising proportion of older
people. In 1970, 25% of all breast cancer patients was 70 years or
older and in 1999 33% (Coebergh et al, 2001). In a population-
based study in the registration area of the Eindhoven Cancer
Registry, the prevalence of comorbidity increased from 10% of
patients younger than 50 to 55% of patients aged 80 years and
older (Louwman et al, submitted). Comorbid conditions may have
an effect on oncological treatment of older breast cancer patients.
Several studies have shown that older patients received less
extensive treatment (like adjuvant radiotherapy and chemother-
apy) (Greenfield et al, 1987; Bergman et al, 1991; Yancik et al,
2001; Bouchardy et al, 2003; Louwman et al, submitted). Few data
exist on treatment results for older breast cancer patients with
serious comorbid conditions, since these patients generally are not
eligible for clinical trials (Hutchins et al, 1999; Kemeny et al, 2003).
Comorbidity may also have a negative impact on prognosis. Some
studies have found that breast cancer patients with comorbid
conditions had a lower overall survival rate compared to patients
without comorbidity (Bergman et al, 1991; Satariano and Ragland,
1994; Yancik et al, 2001; Louwman et al, submitted).
In this study, we investigated whether age and serious comorbid
conditions influenced treatment decisions, the occurrence of
serious complications within 1 year after diagnosis and survival
in breast cancer patients.
MATERIALS AND METHODS
Study population
The Eindhoven Cancer Registry (ECR) has collected data on all
patients with newly diagnosed cancer in the Dutch province of
North Brabant and in the northern part of the adjacent province of
Limburg. The registry serves a population of about 2 million
inhabitants. Information on diagnosis, staging, treatment and
comorbidity (since 1993) were extracted from the medical records.
The area offers good access to specialised medical care supplied in
12 general hospitals and two large radiotherapy institutes.
For this study, a random sample was taken from the database of
the Eindhoven Cancer Registry (function uniform in the SAS
computer package). This sample consisted of 549 women aged 40
years and older with breast cancer, diagnosed between 1995 and
1999 in eight out of 12 general hospitals in the registration area.
This sample size was considered large enough for subgroup
analyses according to time and costs of review of medical records.
Of these 549 patients, 22 patients were excluded for the following
reasons. In all, 14 clinical records could not be found in the
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lhospitals due to migration, death or unknown reasons and eight
clinical records were incomplete. These excluded patients had a
mean age of 68 years (compared to 62 years for those in the study)
and 59% died during follow-up (compared to 25% deaths in the
study). Data of the other 527 patients were included for analyses.
Measurements
With the approval of the treating physicians, two researchers (an
epidemiologist (SH) and a surgeon (CV)) extracted additional
information on severity of comorbidity, complications and
performance status from the medical records. Severity of
comorbidity was classified as high, moderate and low impact
according to the conceptual model ‘Life Threat’ (Yancik et al,
1998) (Table 1). We did not include the category ‘negligible
impact’ in our study, because we assume that the influence of these
comorbid conditions on treatment and prognosis would have been
negligible and similar to that of patients without comorbidity. For
analyses of treatment, complications and survival, patients with
more comorbid conditions were classified according to the most
severe condition.
The functional status of the patient was extracted from the
medical record, using the Karnofsky scale (Karnofsky et al, 1948).
Five categories were distinguished according to the Eastern Co-
operative Oncology Group (ECOG). For surgical patients, we also
recorded the American Society of Anaesthesiologists (ASA)
physical status score (House of Delegates of the American Society
of Anesthesiologists, 1963). However, it proved to be impossible to
include functional status and the ASA score in the analyses,
because for 68% of the breast cancer patients, the functional status
was not found in the medical record and for 45% the ASA score
was missing.
Treatment was classified as surgery, surgery plus radiotherapy,
surgery plus radiotherapy plus systemic therapy (chemotherapy
and/or hormonal therapy), surgery plus systemic therapy and
other therapy. Axillary nodal status was recorded on the basis of
clinical and pathological examination.
Serious complications were recorded during the first year after
diagnosis. Complications registered were minor infections (such as
superficial wound infection), major infections (such as abscess,
septicaemia), pulmonary complications (such as pneumonia),
haemorrhage (requiring blood transfusion or surgery), throm-
boembolic complications, cardiac problems (such as cardiac
insufficiency), complications due to radiotherapy (such as
pneumonitis) or chemotherapy (such as severe nausea), lymphoe-
dema and other complications.
Information on vital status of the patients was obtained from the
hospital records and the death register of the Central Bureau for
Genealogy. Follow-up was completed until 1 July 2003 (mean
follow-up 4.7 years).
Statistical analysis
The association between severity of comorbidity and treatment
and number of complications (0, 1 and X2) was analysed
according to age. Differences between subgroups were tested with
the w
2 test. Univariate crude 5-year survival rates were calculated
according to severity of comorbidity, axillary nodal status,
treatment and age. Survival time was defined as the time from
diagnosis until death or the end of the study (if the patient was still
alive on 1 July 2003). Differences in crude survival between
categories were tested with the log-rank test. In a multivariable
Cox’s proportional-hazard regression analysis, independent ha-
zard ratios (HR) for severity of comorbidity were estimated and
adjusted for age at diagnosis, axillary nodal status and treatment.
Survival generally decreases with age and the prevalence of
comorbidity increases with age. Therefore, we estimated relative
survival rates. Relative survival rates were calculated as the ratio of
observed survival in the cancer patients divided by the expected
survival of a group of individuals of closely similar age from the
general population. The SAS computer package (version 8.2) was
used for all statistical analyses (SAS Institute Inc., Cary, North
Carolina, USA, 1999).
RESULTS
For this study, we extracted a random sample of women aged 40
years and older with breast cancer from a population-based
database. The distribution of age, stage and vital status in the
random sample was similar to that in the whole database of the
Eindhoven Cancer Registry. In total, 373 breast cancer patients
were aged between 40 and 69 years and 154 patients were 70 years
and older.
In all, 77% of the patients aged 40–49 years had no concomitant
disease, whereas this was only 6% of those aged 80 years and older
(Figure 1). High impact concomitant diseases were most prevalent
among older patients (72% of those aged 80 years and older vs 6%
of those aged 40–49 years).
The most common condition with high impact was hypertension
under active treatment (12% of patients aged o70 years and 32%
of patients aged X70 years). In all, 7% of younger patients had
cardiovascular diseases with high impact compared to almost 25%
of older patients. Diabetes, both low and high impact, occurred
more frequently in patients aged 70 years and older (10 and 8%,
respectively) than in patients aged 40–69 years (2 and 3%,
respectively).
Overall, patients aged 70 years and older received significantly
less radiotherapy and chemotherapy and significantly more
hormonal therapy than patients under 70 years did (results not
shown). The percentage of patients aged X70 years receiving
surgery and radiotherapy was 25% compared to 38% of those aged
o70 years. Of patients aged 70 years and older, o1% received
chemotherapy and 44% hormonal therapy compared to 17 and
25%, respectively, of patients younger than 70 years. For patients
younger than 70, treatment was not influenced by severity of
comorbidity (Figure 2). Patients aged 70 years and older with high
impact comorbidity received slightly more often surgery combined
with systemic therapy, and less surgery alone or surgery in
combination with radiotherapy, but this was not significant
(P¼0.7). Splitting up the variable systemic therapy in hormonal
Table 1 Classification of severity of comorbidity, according to an
adapted version of the model ‘Life Threat’ (Yancik et al, 1998)
High impact Moderate impact Low impact
Angina
a Angina
b Arrhythmia
b
Arrythmia
a Cardiovascular diseases
b Alzheimer’s disease
a,b
Cardiac arrest
a,b Myocardial infarction
b Arthritis
a
Congestive heart failure
a,b Valve disease
b Diabetes (medication
unknown)
a
Cardiovascular disease
a Anaemia
a Eye problems
a
Myocardial infarction
a Asthma
a Fracture
a
Valve disease
a Depression
a Hearing
a
Other heart problems
a Deep vein thrombosis
a Hypertension
b
Chronic obstructive Gastrointestinal
a Liver problems
b
Pulmonary disease
a,b Hypertension
a Obesity
a
Diabetes (insulin)
a Lipid problems
a Osteoporosis
a
Previous cancer
a Liver problems
a Parkinson’s disease
a
Renal failure
a,b Mental health
a Previous cancer
b
Stroke/TIA
a Stroke/TIA
b
Thyroid/glandular
a
Urinary tract (any Hx)
a,b
aUnder active treatment.
bNo current treatment, history only. TIA¼transient
ischaemic attack. Hx¼history.
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ltherapy and chemotherapy showed no association between type of
systemic treatment and severity of comorbidity in patients aged
40–69 years (P¼0.31) and in those aged 70 years and older
(P¼0.35) (data not shown). There was no relationship between
type of surgery (breast conserving therapy or mastectomy with or
without axillary dissection) and severity of comorbidity (data not
shown). In all, 46% of the patients aged 40–69 years without
comorbidity were treated with breast conserving therapy with
axillary dissection compared to 47% of the patients with high
severity of comorbidity. Of those aged 70 years and older, these
percentages were 35 and 23%, respectively (P¼0.7).
The number of patients with complications after surgery was
similar for both age groups (27% of those aged younger than 70
years and 26% of those aged 70 years and older) (Table 2). Patients
aged 80 years and older had somewhat less complications (15%).
Minor infection (10–12%) was the most common complication,
followed by lymphoedema (7–8%). Complications following
radiotherapy were more prevalent in patients younger than 70
(3%) than of those aged 70 years and older (1%). The proportion
of patients aged 70 years and older with two or more complications
was 0% of those without comorbidity, 6% of those with low
severity, 10% of those with moderate severity and only 1% of those
with high severity of comorbidity. There was no statistically
significant difference in both age groups between the number of
complications and the severity of comorbidity (P¼0.6 of patients
younger than 70 years and P¼0.3 of those aged 70 years and
older) (Figure 3).
The 5-year survival for patients without comorbidity was 91%
for those younger than 70 years and 78% for those aged 70 years
and older (Table 3). Of patients aged 40–69 years, the 5-year
survival rate for those with low/moderate and high impact of
comorbidity was significantly lower than for patients without
comorbidity (84 and 80%, respectively, vs 91%). The prognosis for
patients aged 70 years and older was significantly worse for those
with high severity of comorbidity (5-year survival 46%). In the
multivariable analyses (adjusted for age at diagnosis, axillary nodal
status and treatment), the risk of dying for patients younger than
70 years was 2.4 times higher for those with low to moderate
comorbidity and 2.9 times higher for those with high impact
comorbidity compared to patients without comorbidity. Patients
aged 70 years and older with low/moderate impact had a
nonsignificant higher risk of dying compared to patients without
comorbidity, whereas patients with high impact comorbidity had a
three times higher risk of dying. Age was also an independent
prognostic factor for patients aged 70 years and older. Treatment
and axillary nodal status were no significant prognostic factors
after adjustment for age and severity of comorbidity. Splitting up
the variable systemic therapy in hormonal therapy and che-
motherapy did not alter the above-mentioned results. Using a
cutoff point in the multivariable analyses of 60 years instead of 70
years still did not alter the results. The 5-year relative survival rate
was not significantly lower in older patients (Table 4). Older
women with high impact comorbidity exhibited lower relative
survival rates compared to those without comorbidity, but this
difference was not significant.
DISCUSSION
This study shows that severe comorbidity at the time of cancer
diagnosis negatively affected survival of breast cancer patients
diagnosed in general hospitals. However, it did not appear to
influence choice of treatment or the occurrence of complications
after treatment.
There was no significant difference in treatment for women with
breast cancer according to severity of comorbidity. This confirms
the results of previous studies (Greenfield et al, 1987; Bergman
et al, 1991), where age was a more important factor for choice of
treatment than comorbidity. In a prospective cohort study among
American breast cancer patients aged 65 years and older, no
association was found between primary therapy and comorbidity
(Lash et al, 2003). However, a study among 1196 breast cancer
patients in the Kaiser Permanente Medical Care Program
demonstrated that patients with two or more comorbid conditions
received less adjuvant breast cancer therapy, such as radiotherapy
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Figure 1 Age-specific prevalence of comorbidity among breast cancer
patients diagnosed in 1995–1999 in the southern Netherlands.
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Figure 2 Treatment (%) of breast cancer patients diagnosed in 1995–
1999 in the southern Netherlands, according to severity of comorbidity and
age. S¼surgery, SþRT¼surgery and radiotherapy, SþRTþST¼surgery
and radiotherapy and systemic therapy, SþST¼surgery and systemic
therapy.
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land chemotherapy (West et al, 1996). In a large population-based
study with all breast cancer patients diagnosed between 1995 and
1999 (N¼6277) in the area of the Eindhoven Cancer Registry
(from which our sample was derived), we found that breast cancer
patients with comorbidity less frequently received adjuvant
radiotherapy (50 vs 65%, Po0.0001) and less extensive surgical
treatment (Louwman et al, submitted). An explanation for this
discrepancy could be that we had too few patients in our random
sample to see this effect. Another explanation could be that
different classification systems for comorbidity were used.
In this population-based study that was carried out in medium-
sized general hospitals in which the caseload was relatively high,
we found no statistically significant difference between the number
of complications and the severity of comorbidity or age.
Complications following radiotherapy, however, were more pre-
valent in patients younger than 70 years compared to those aged 70
years and older, even after the adjustment for the higher
proportion of younger patients receiving radiotherapy. Younger
patients, however, did not receive a higher dose of radiotherapy.
We are not aware of any other study describing the effect of
comorbidity on postoperative complications in older breast cancer
patients. Of patients who underwent prostatectomy, comorbidity
and age did not significantly affect complications, but comorbid
conditions did prolong postoperative bed-stay (Ibrahim et al,
1995). The latter was not recorded in this study.
Prognosis of breast cancer patients with severe comorbidity was
significantly worse compared to patients without comorbidity after
adjustment for age, axillary nodal status and treatment. Other
studies also showed that breast cancer patients with comorbidity
had a lower survival rate compared to patients without comorbid-
ity, regardless of other prognostic factors such as age and stage of
breast cancer at diagnosis (Bergman et al, 1991; West et al, 1996;
Yancik et al, 2001; Louwman et al, submitted). In a longitudinal
observational study carried out in the Detroit metropolitan area
among women aged 40–84 years, patients with three or more
comorbidities even had a 20-fold higher rate of mortality from
causes other than breast cancer and a four-fold higher rate of all-
cause mortality compared to patients without comorbidity
(Satariano and Ragland, 1994). This means that breast cancer,
and perhaps its treatment, may accelerate the course of other
pathologic conditions, which might increase the risk of death from
those conditions.
Owing to the relatively small number of breast cancer patients in
this study, the effect of the individual comorbid conditions on
prognosis could not be analysed.
Comparing the results of the above-mentioned studies, we have
to take into account that the comorbidity measures used were
somewhat different. In several studies (Newschaffer et al, 1996;
West et al, 1996; Lash et al, 2003), the Charlson comorbidity
method (Charlson et al, 1987) was used to measure comorbidity
and in other studies (Greenfield et al, 1987; Bergman et al, 1991)
another measure of comorbidity was used. Although the effect of
severity of comorbidity according to the ‘Life Threat’ model
(Yancik et al, 1998) has not yet been validated in breast cancer, we
believe it to be the best available index to measure severity of
comorbidity in which information about treatment of the
comorbid condition was included. Besides this, the measure was
shown to predict survival in a large population-based study of
colorectal cancer patients (Yancik et al, 1998). Therefore, we are
not surprised to find that severity of comorbidity, measured
according to the ‘Life Threat’ model, was a strong prognostic factor
in our study.
We extracted data from the patient’s medical record as these are
generally regarded as the most complete source of information on
the patient’s past and current health status (Satariano, 2000).
However, specific information like functional status and ASA score
was not consistently available across hospitals and patients.
Therefore, we could not include these prognostic factors in our
analyses.
Studies including older cancer patients should asses comorbid-
ity and functional status separately, because they predict survival
in older cancer patients in a different way (Extermann et al, 1998).
The correlation between the ECOG performance status score and
the Charlson comorbidity scale was only 0.14. Functional status
may reflect an interactive process between cancer stage and
comorbidity level, in which psychosocial factors may act as
Table 2 Age-specific prevalence of complications during the first year
after diagnosis for breast cancer patients diagnosed in 1995–1999 in the
southern Netherlands
o70 years X70 years
Type of complication
a % (N) % (N)
No complication 71.1% (265) 69.5% (107)
Minor infection (like superficial
wound infection)
11.5% (43) 9.7% (15)
Major infection (like abscess,
septicaemia)
3.2% (12) 4.6% (7)
Pulmonary (like pneumonia) 0.8% (3) 1.3% (2)
Haemorrhage (requiring blood
transfusion or surgery)
3.5% (13) 3.3% (5)
Thromboembolic 0.0% (0) 0.7% (1)
Cardiac (like cardiac insufficiency) 0.3% (1) 1.3% (2)
Following radiotherapy (like
pneumonitis)
b
3.5% (8) 1.4% (1)
Following systemic therapy (like
severe nausea)
c
1.5% (2) 0.0% (0)
Lymphoedema
d 7.7% (25) 7.0% (8)
Other 3.5% (13) 2.0% (3)
Unknown 1.9% (7) 4.6% (7)
aMore complications per patient possible.
bProportion of patients who underwent
radiotherapy.
cProportion of patients who underwent chemotherapy.
dProportion of
patients who underwent axillary dissection.
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Figure 3 Number of complications (%) during the first year after
diagnosis among breast cancer patients diagnosed in 1995–1999 in the
southern Netherlands, according to severity of comorbidity and age.
compl¼complications.
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lconfounders. Apart from this, comorbidity and a deterioration in
functional status of patients aged 70 years and older led to greater
heterogeneity and therefore more individualisation of treatment
protocols (Hillen and Hupperets, 2000).
We estimated crude 5-year survival rates. It is expected that the
survival rate of older breast cancer patients is worse. Since the
prevalence of comorbidity also increases with age, this could have
biased our results. However, comorbidity retained its prognostic
value after adjustment for age. The relation between comorbidity
and survival was somewhat weaker but comparable if relative
survival rates were calculated. Unfortunately, we had no data on
cause of death of our patients, so we could not give cause-specific
survival rates.
Until now, there is not enough evidence that the biological effect
of treatment, like toxicity of chemotherapy and radiotherapy, is
different for older breast cancer patients with comorbidity than for
younger patients. Elderly breast cancer patients (aged 65 years and
older) are under-represented in treatment trials. A review of 164
trials carried out by the Southwest Oncology Group showed that
49% of the total breast cancer population under investigation was
aged 65 years and older and only 9% of them was included in
clinical trials (Hutchins et al, 1999). It is therefore important that
more trials are initiated that include older cancer patients in order
to establish the outcome in the elderly.
In conclusion, we found that older breast cancer patients with
serious comorbidity were generally not treated differently and
hardly had more complications. Prognosis of breast cancer
patients was influenced negatively by severe comorbidity only.
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